1-allyloxycarbonyloxymethyl-5-fluorouracil

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-allyloxycarbonyloxymethyl-5-fluorouracil
• 英文别名: (5-Fluoro-2,4-dioxopyrimidin-1-yl)methyl prop-2-enyl carbonate；(5-fluoro-2,4-dioxopyrimidin-1-yl)methyl prop-2-enyl carbonate
• 化学式: C₉H₉FN₂O₅
• 分子量: 244.179
• InChiKey: KYZGEMYTVDYRAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  84.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  聚合甲醛 、 5-氟脲嘧啶 、 氯甲酸烯丙酯 在 TEA 作用下， 以 水 、 乙腈 为溶剂， 反应 51.0h， 生成 1-allyloxycarbonyloxymethyl-5-fluorouracil 、 1,3-bis(allyloxycarbonyloxymethyl)-5-fluorouracil
  参考文献：
  名称：

  Synthesis of allyloxycarbonyloxymethyl-5-fluorouracil and copolymerizations with N-vinylpyrrolidinone

  摘要：

  Poly(N-vinylpyrrolidinone) (PNVP) bearing 5-fluorouracil (5-FU) moieties was synthesised via a three-step method. Firstly, 5-FU reacted with formaldehyde to form a mixture of mono- and disubstituted hydroxymethyl-5-FUs. The mixture was then treated with allyl chloroformate to afford allyloxycarbonyloxymethyl-5-FUs. This reaction showed site-specificity: the hydroxymethyl goup at the N-1 position readily reacted with chloroformate whereas the N-3 hydroxymethyl group partially decomposed into formaldehyde and the amide group. 1-Allyloxycarbonyloxymethyl-5-FU (4) and NVP were copolymerized in dioxane using azobisisobutyronitrile as an initiator. The monomer reactivity ratios, r(4) = 0.32 and r(NVP) = 0.97, were evaluated by both linear and non-linear methods.

  DOI：

  10.1039/b002092n

文献信息

• [EN] CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS<br/>[FR] SUPPORTS SOLIDES POUR LA LIBÉRATION CONTRÔLÉE DE MÉDICAMENTS
  申请人：PROLYNX LLC

  公开号：WO2011140392A1

  公开（公告）日：2011-11-10

  The invention relates to solid supports useful in medical applications that provide controlled release of drugs, such as peptides, nucleic acids and small molecules. The drugs are covalently coupled to the solid support through a linkage that releases the drug or a prodrug through controlled beta elimination.

  这项发明涉及在医疗应用中有用的固体支持物，可提供药物的控制释放，如肽、核酸和小分子。这些药物通过一个通过受控β消除释放药物或前药的连接与固体支持物共价偶联。
• [EN] CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES<br/>[FR] LIBÉRATION CONTRÔLÉE À PARTIR DE CONJUGUÉS MACROMOLÉCULAIRES
  申请人：PROLYNX LLC

  公开号：WO2011140393A1

  公开（公告）日：2011-11-10

  The invention relates to conjugates of macromolecular carriers and drugs comprising linkers that release the drug or a prodrug through rate-controlled beta-elimination, and methods of making and using the conjugates.

  这项发明涉及大分子载体和药物的共轭物，包括释放药物或前药的连接剂，通过速率控制的β-消除释放药物，以及制备和使用这些共轭物的方法。
• CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES
  申请人：Ashley Gary

  公开号：US20130116407A1

  公开（公告）日：2013-05-09

  The invention relates to conjugates of macromolecular carriers and drugs comprising linkers that release the drug or a prodrug through rate-controlled beta-elimination, and methods of making and using the conjugates.

  该发明涉及大分子载体和药物的共轭物，包括通过速率控制的β-消除释放药物或前药的连接剂，以及制备和使用这些共轭物的方法。
• CONTROLLED DRUG RELEASE FROM DENDRIMERS
  申请人：Ashley Gary

  公开号：US20130123461A1

  公开（公告）日：2013-05-16

  The invention relates to compositions that comprise dendrimers useful in medical and veterinary applications that provide controlled release of drugs, such as peptides, nucleic acids and small molecules. The drugs are covalently coupled to the dendrimer through a linkage that releases the drug or a prodrug through controlled beta elimination.

  本发明涉及一种包含树状分子的组合物，该组合物在医疗和兽医应用中有用，能够提供药物的控制释放，例如肽，核酸和小分子。药物通过一个连接与树状分子共价耦合，该连接通过控制的β消除释放药物或前药。
• CONTROLLED RELEASE FROM SOLID SUPPORTS
  申请人：Ashley Gary

  公开号：US20130123487A1

  公开（公告）日：2013-05-16

  The invention relates to solid supports useful in medical applications that provide controlled release of drugs, such as peptides, nucleic acids and small molecules. The drugs are covalently coupled to the solid support through a linkage that releases the drug or a prodrug through controlled beta elimination.

  本发明涉及固体支持在医学应用中的使用，提供药物的控制释放，例如肽、核酸和小分子。药物通过一个连接环节共价耦合到固体支持上，通过受控的β消除释放药物或前药。